DMD and meningioma: In addition, although our NGS panel enables a broad survey of known cancer genes, it does not screen for relevant genomic alterations such as DMD deletions or TERT gene translocations both of which have been shown to be associated with a poor outcome in progressive/high-grade meningiomas [20].